CD8A and cancer: In a clinical trial, patients with cancer with NSCLC who received oral calcitriol (1α,25(OH)2D3) showed decreased cell-surface level of PD-1, Tim-3 and TIGIT and increased CD28 expression on Vγ9Vδ2+ and CD8+ T cells.